VANCOUVER, British Columbia – TheNewswire - March 31, 2026 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company, today announced that it has completed the previously announced sale of its ZIMED® PF product to Luvo Medical Technologies Ltd. (“Luvo”) for aggregate consideration of approximately $531,693 (the “Transaction”). As the Transaction constituted the sale of all or substantially all of the assets of the Company pursuant to Section 301 of the Busin ...